ORIC Pharmaceuticals
South San Francisco
About ORIC Pharmaceuticals
ORIC Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to improving patients’ lives by Overcoming Resistance In Cancer. ORIC’s lead product candidate, ORIC-101, is a potent and selective small molecule antagonist of the glucocorticoid receptor, which has been linked to resistance to multiple classes of cancer therapeutics across a variety of solid tumors. ORIC’s second product candidate, ORIC-533, is an orally bioavailable small molecule inhibitor of CD73, a key node in the adenosine pathway believed to play a central role in resistance to chemotherapy- and immunotherapy-based treatment regimens. Beyond these two product candidates, ORIC is also developing multiple precision medicines targeting other hallmark cancer resistance mechanisms. ORIC’s scientific founders, Charles Sawyers, MD, and Scott Lowe, Ph.D., have long records of discovering novel targets in cancer that have led to innovative treatments.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 101 – 250
- Total funding: $533.0M
- Funding stage: IPO
- Last round: Post-IPO Equity (May 2025)
- Ticker: nasdaq:ORIC
- Website: oricpharma.com
- Phone: (650)388-5600
Industries & Categories
Biopharma, Biotechnology, Health Care, Pharmaceutical, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/oric-pharmaceuticals-16023 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.